Ekol Eye Hospital, Izmir, Turkey.
Int Ophthalmol. 2021 Feb;41(2):491-498. doi: 10.1007/s10792-020-01599-8. Epub 2021 Jan 3.
The aim of this study was to compare the distance, intermediate, and near visual performance of a new IOL (ICB00, Eyhance, Tecnis) and classic monofocal IOL (SN60WF IQ AcrySof, Alcon) after unilateral implantation.
Sixty-three patients were unilaterally implanted with the ICB00 Eyhance IOL (study group) and 65 patients with the SN60WF IQ AcrySof (control group). Visual performance was assessed with monocular corrected distance visual acuity (CDVA) and uncorrected distance visual acuity (UDVA) at 4 m, corrected intermediate visual acuity (CIVA) and uncorrected intermediate visual acuity (UIVA) at 60 cm, and corrected near visual acuity (CNVA) and uncorrected near visual acuity (UNVA) at 40 cm.
CDVA, UDVA, CNVA, and UNVA values did not differ significantly between the study and control groups (0.02 ± 0.02 vs. 0.03 ± 0.02, p = 0.523; 0.05 ± 0.13 vs. 0.05 ± 0.15, p = 0.637; 0.46 ± 0.17 vs. 0.46 ± 0.15, p = 0.821; and 0.47 ± 0.21 vs. 0.49 ± 0.25, p = 0.612; respectively), whereas the study group showed significantly better results for CIVA (0.28 ± 0.12 vs. 0.38 ± 0.13, p = 0.001) and UIVA (0.31 ± 0.16 vs. 0.41 ± 0.12, p = 0.001).
The Eyhance IOL, which features a new optical design based on a continuous power profile, was determined to be superior to a classic monofocal IOL for intermediate visual acuity and not inferior for corrected and uncorrected distance and near visual acuity.
本研究旨在比较新型人工晶状体(ICB00,Eyhance,Tecnis)和经典单焦点人工晶状体(SN60WF IQ AcrySof,Alcon)单侧植入后的远、中、近视力。
63 例患者单侧植入 ICB00 Eyhance 人工晶状体(研究组),65 例患者植入 SN60WF IQ AcrySof(对照组)。使用单眼矫正远视力(CDVA)和未矫正远视力(UDVA)在 4 m 处,矫正中间视力(CIVA)和未矫正中间视力(UIVA)在 60 cm 处,矫正近视力(CNVA)和未矫正近视力(UNVA)在 40 cm 处评估视觉表现。
研究组与对照组的 CDVA、UDVA、CNVA 和 UNVA 差异无统计学意义(0.02±0.02 与 0.03±0.02,p=0.523;0.05±0.13 与 0.05±0.15,p=0.637;0.46±0.17 与 0.46±0.15,p=0.821;0.47±0.21 与 0.49±0.25,p=0.612),但研究组 CIVA(0.28±0.12 与 0.38±0.13,p=0.001)和 UIVA(0.31±0.16 与 0.41±0.12,p=0.001)的结果明显更好。
基于连续功率分布的新型光学设计的 Eyhance 人工晶状体被确定在中间视力方面优于经典单焦点人工晶状体,而在矫正和未矫正的远、近视力方面则没有劣势。